Tobira Therapeutics Inc. Company Profile

News Articles [ 14 Associated News Articles listed on BioPortfolio]

Tobira Therapeutics to Present at the 31st Annual J. P. Morgan Healthcare Conference

Tobira Therapeutics announced today that it will be presenting at the 31st Annual J. P. Morgan Healthcare Conference in San Francisco. Andrew Hindman, Tobira’s President and CEO...

Tobira reports first Phase IIb data for HIV compound

Tobira Therapeutics Inc. (San Francisco, Calif.) said once-daily cenicriviroc plus Truvada emtricitabine/tenofovir from Gilead Sciences Inc. (NASDAQ:GILD) met the primary endpoint in the Phase IIb (St...

Tobira dual CCR5/CCR2 inhibitor efficacy comparable, safety better than Sustiva in Phase IIb for HIV

Tobira Therapeutics' oral, once-daily HIV drug cenicriviroc (CVC) was just as effective as Sustiva (efavirenz) and had a better safety profile than the Bristol-Myers Squibb drug in a Phase I...

Tobira dual CCR5/CCR2 inhibitor efficacy comparable, safety better than Sustiva in Phase IIb for HIV

Tobira Therapeutics' oral, once-daily HIV drug cenicriviroc (CVC) was just as effective as Sustiva (efavirenz) and had a better safety profile than the Bristol-Myers Squibb drug in a Phase IIb clini...

Tobira Therapeutics Presents Positive Phase 2b Clinical Results For Cenicriviroc in Treatment-Naïve HIV Infection in Late Breaker Session at CROI

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 5, 2013 - Tobira Therapeutics presented positive results from the Phase 2b clinical trial (Study 202) of cenicriviroc (CVC) today at the 20th Conferen...

Tobira Pegs Nodality Vet Andrew Hindman as CEO

Tobira Therapeutics, a Manalapan, NJ-based developer of therapies to treat HIV, has named Andrew Hindman president and CEO, according to a news release. Hindman was most recently senior v.p. of develo...

Tobira Therapeutics Announces Positive 24-Week Primary Analysis From Phase 2b Trial of Cenicriviroc in Treatment-Naïve HIV Infection

Results Support Advancement to Phase 3 Registrational Studies SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan 7, 2013 - Tobira Therapeutics today announced positive results from the 24-week primary...

Tobira Therapeutics Announces Positive 24-Week Primary Analysis From Phase 2b Trial of Cenicriviroc in Treatment-Naïve HIV Infection

Tobira Therapeutics today announced positive results from the 24-week primary analysis of Study 202, the Phase 2b study of cenicriviroc (CVC). CVC is a novel, oral, once-daily, du...

Drugs and Medications [0 Results]

None

PubMed Articles [ 2 Associated PubMed Articles listed on BioPortfolio]

Cadmium stabilization with nursery stocks through transplantation: A new approach to phytoremediation.

Disposal of heavy metal contaminated biomass after phytoremediation is still unfeasible. This paper presents a viable phyto-extraction approach in which metals in contaminated soils are stabilized by...

Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010.

Introduction: HIV/AIDS is one of the most devastating diseases in the world affecting > 40 million people worldwide. Morbidity and mortality from AIDS are significantly reduced due to the advent of hi...

Clinical Trials [0 Results]

None

Companies [ 2 Associated Companies listed on BioPortfolio]

Tobira Therapeutics, Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Ec...

Tobira Therapeutics Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by E...